Mocertatug rezetecan: Clinical Trials

5 trials of Mocertatug rezetecan, newest first

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

4 recruiting, 1 not yet recruiting. 4 Phase 3, 1 Phase 1.

By phase and status

Phase	Trials	Status
Phase 3	4	Recruiting 3, Not yet recruiting 1
Phase 1	1	Recruiting 1

Follow Mocertatug rezetecan: new trials by email Literature Review of Mocertatug rezetecan trials Research Report on Mocertatug rezetecan

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Mo-Rez in First- Line (1L) Maintenance Treatment of Non-Homologous Recombination Deficient Ovarian Cancer (Non-HRd OC) [BEHOLD-Ovarian03] Mocertatug rezetecan, Bevacizumab - Ovarian Neoplasms	Phase 3	Not yet recruiting	GlaxoSmithKline	720	2026-10-09	2026-10-02
A Study to Investigate Mocertatug Rezetecan as Maintenance Treatment for Participants With MMRp Endometrial Cancer (BEHOLD-Endometrial02) Mocertatug rezetecan, Dostarlimab, Pembrolizumab - Neoplasms, Endometrial	Phase 3	Recruiting	GlaxoSmithKline	610	2026-09-24	2026-10-15
A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01) Mocertatug rezetecan, Paclitaxel, Pegylated liposomal doxorubicin (PLD) - Ovarian Neoplasms	Phase 3	Recruiting	GlaxoSmithKline	450	2026-06-18	2026-10-15
A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01) Mocertatug rezetecan, Paclitaxel, Doxorubicin - Neoplasms, Endometrial	Phase 3	Recruiting	GlaxoSmithKline	600	2026-06-04	2026-10-02
A Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Participants With Advanced Solid Tumors (BEHOLD-1) Mocertatug rezetecan - Solid Tumors, Neoplasms	Phase 1	Recruiting	GlaxoSmithKline	675	2024-07-02	2026-06-25

Conditions studied

Sponsors

Countries

Results publications

NIH funding